Perspective Therapeutics, Inc. (NYSE:CATX) Shares Bought by State Street Corp

State Street Corp grew its position in Perspective Therapeutics, Inc. (NYSE:CATX) by 119.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 2,190,239 shares of the company’s stock after purchasing an additional 1,192,812 shares during the period. State Street Corp’s holdings in Perspective Therapeutics were worth $29,240,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. nVerses Capital LLC purchased a new position in Perspective Therapeutics during the third quarter worth $57,000. US Bancorp DE boosted its stake in shares of Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Perspective Therapeutics during the 3rd quarter worth about $137,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Perspective Therapeutics in the 3rd quarter valued at about $152,000. Finally, Los Angeles Capital Management LLC purchased a new position in Perspective Therapeutics in the 3rd quarter valued at about $153,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Oppenheimer cut their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Royal Bank of Canada reduced their price target on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, November 25th. UBS Group initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Finally, Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $24.00 to $5.00 in a report on Monday, November 25th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.14.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $2.85 on Friday. The firm has a fifty day moving average of $7.79 and a 200-day moving average of $11.12. Perspective Therapeutics, Inc. has a 52-week low of $2.70 and a 52-week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The firm had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. On average, sell-side analysts predict that Perspective Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.

Insider Activity at Perspective Therapeutics

In other news, CEO Johan M. Spoor acquired 14,500 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was bought at an average cost of $3.78 per share, with a total value of $54,810.00. Following the transaction, the chief executive officer now directly owns 152,072 shares in the company, valued at approximately $574,832.16. This represents a 10.54 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jonathan Robert Hunt bought 12,829 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were acquired at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the transaction, the chief financial officer now owns 48,800 shares of the company’s stock, valued at approximately $186,416. The trade was a 35.66 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 67,570 shares of company stock worth $256,789. 3.52% of the stock is currently owned by company insiders.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.